Literature DB >> 16982618

Mu opioid receptor activation of ERK1/2 is GRK3 and arrestin dependent in striatal neurons.

Tara A Macey1, Janet D Lowe, Charles Chavkin.   

Abstract

In this study we investigated the mechanisms responsible for MAP kinase ERK1/2 activation following agonist activation of endogenous mu opioid receptors (MOR) normally expressed in cultured striatal neurons. Treatment with the MOR agonist fentanyl caused significant activation of ERK1/2 in neurons derived from wild type mice. Fentanyl effects were blocked by the opioid antagonist naloxone and were not evident in neurons derived from MOR knock-out (-/-) mice. In contrast, ERK1/2 activation by fentanyl was not evident in neurons from GRK3-/- mice or neurons pretreated with small inhibitory RNA for arrestin3. Consistent with this observation, treatment with the opiate morphine (which is less able to activate arrestin) did not elicit ERK1/2 activation in wild type neurons; however, transfection of arrestin3-(R170E) (a dominant positive form of arrestin that does not require receptor phosphorylation for activation) enabled morphine activation of ERK1/2. In addition, activation of ERK1/2 by fentanyl and morphine was rescued in GRK3-/- neurons following transfection with dominant positive arrestin3-(R170E). The activation of ERK1/2 appeared to be selective as p38 MAP kinase activation was not increased by either fentanyl or morphine treatment in neurons from wild type, MOR-/-, or GRK3-/- mice. In addition, U0126 (a selective inhibitor of MEK kinase responsible for ERK phosphorylation) blocked ERK1/2 activation by fentanyl. These results support the hypothesis that MOR activation of ERK1/2 requires opioid receptor phosphorylation by GRK3 and association of arrestin3 to initiate the cascade resulting in ERK1/2 phosphorylation in striatal neurons.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982618      PMCID: PMC2104781          DOI: 10.1074/jbc.M604278200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction.

Authors:  J L Whistler; H H Chuang; P Chu; L Y Jan; M von Zastrow
Journal:  Neuron       Date:  1999-08       Impact factor: 17.173

2.  G protein-coupled receptor kinase 3 (GRK3) gene disruption leads to loss of odorant receptor desensitization.

Authors:  K Peppel; I Boekhoff; P McDonald; H Breer; M G Caron; R J Lefkowitz
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

3.  Mu and delta opioid receptors are differentially desensitized by the coexpression of beta-adrenergic receptor kinase 2 and beta-arrestin 2 in xenopus oocytes.

Authors:  A Kovoor; V Nappey; B L Kieffer; C Chavkin
Journal:  J Biol Chem       Date:  1997-10-31       Impact factor: 5.157

4.  Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness.

Authors:  J Zhang; S S Ferguson; L S Barak; S R Bodduluri; S A Laporte; P Y Law; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

5.  Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1.

Authors:  A G Schuller; M A King; J Zhang; E Bolan; Y X Pan; D J Morgan; A Chang; M E Czick; E M Unterwald; G W Pasternak; J E Pintar
Journal:  Nat Neurosci       Date:  1999-02       Impact factor: 24.884

6.  Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gbetagamma subunits.

Authors:  M M Belcheva; Z Vogel; E Ignatova; T Avidor-Reiss; R Zippel; R Levy; E C Young; J Barg; C J Coscia
Journal:  J Neurochem       Date:  1998-02       Impact factor: 5.372

Review 7.  The stress-activated protein kinase pathways.

Authors:  L A Tibbles; J R Woodgett
Journal:  Cell Mol Life Sci       Date:  1999-08-15       Impact factor: 9.261

8.  Targeted construction of phosphorylation-independent beta-arrestin mutants with constitutive activity in cells.

Authors:  A Kovoor; J Celver; R I Abdryashitov; C Chavkin; V V Gurevich
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

9.  Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy.

Authors:  A Kovoor; J P Celver; A Wu; C Chavkin
Journal:  Mol Pharmacol       Date:  1998-10       Impact factor: 4.436

10.  Preferential Interaction between the dopamine D2 receptor and Arrestin2 in neostriatal neurons.

Authors:  Tara A Macey; Vsevolod V Gurevich; Kim A Neve
Journal:  Mol Pharmacol       Date:  2004-09-10       Impact factor: 4.436

View more
  40 in total

Review 1.  Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction.

Authors:  K Defea
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat.

Authors:  Tara A Macey; Erin N Bobeck; Deborah M Hegarty; Sue A Aicher; Susan L Ingram; Michael M Morgan
Journal:  J Pharmacol Exp Ther       Date:  2009-08-14       Impact factor: 4.030

Review 4.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

5.  A single mutation in arrestin-2 prevents ERK1/2 activation by reducing c-Raf1 binding.

Authors:  Sergio Coffa; Maya Breitman; Benjamin W Spiller; Vsevolod V Gurevich
Journal:  Biochemistry       Date:  2011-07-13       Impact factor: 3.162

Review 6.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

7.  Ligand-biased activation of extracellular signal-regulated kinase 1/2 leads to differences in opioid induced antinociception and tolerance.

Authors:  Erin N Bobeck; Susan L Ingram; Sam M Hermes; Sue A Aicher; Michael M Morgan
Journal:  Behav Brain Res       Date:  2015-10-20       Impact factor: 3.332

8.  Inducible expression of functional mu opioid receptors in murine dendritic cells.

Authors:  Zheng-Hong Li; Niansheng Chu; Li-Dong Shan; Shan Gong; Qi-Zhang Yin; Xing-Hong Jiang
Journal:  J Neuroimmune Pharmacol       Date:  2009-02-03       Impact factor: 4.147

Review 9.  β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  Handb Exp Pharmacol       Date:  2014

10.  Enhanced phosphorylation-independent arrestins and gene therapy.

Authors:  Vsevolod V Gurevich; Xiufeng Song; Sergey A Vishnivetskiy; Eugenia V Gurevich
Journal:  Handb Exp Pharmacol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.